Furthermore, the intrinsic vascular permeability characteristic of GBM may facilitate the selective accumulation of suitably engineered therapeutics, thereby enabling targeted modulation of NUCB2 within the GBM tumour microenvironment. The gene discussed is NUCB2; the disease is neoplasm.